GlobeNewswire·Aug 26, 2026, 8:30 AM ET

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

AMIX

Autonomix Medical, Inc. received U.S. Patent No. 12,714,780 from the USPTO on August 25, 2026, titled "Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development."
The patent protects systems integrating surgical instruments, controllers, sensing, imaging, & controlled therapeutic delivery based on physiological feedback signals from targeted tissues.
Specific applications include regulating therapeutic fluid distribution, using denervating agents, & performing neural ablation to reduce cancer pain in tumor regions.
The patent covers monitoring, imaging, stimulating, & ablating neurological structures associated with the lower urinary tract & modulating organ function, hormone secretion, or tumor growth.
Treatment guidance may utilize minimally invasive transvascular routes through arteries & veins, guided by physiological & electrophysiological feedback.
The patent application traces back to original filings from 2012 & 2014, reflecting a long development history for the underlying technology.
Autonomix's investigational platform features a catheter-based microchip sensing array designed for transvascular diagnosis & treatment of peripheral nervous system diseases.
Initial clinical trials focus on treating pain associated with pancreatic cancer, with potential future applications in cardiology, hypertension, & chronic pain management.
The company's technology remains investigational & has not yet received clearance for marketing in the United States.